The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog, to improve glycemic control in patients with diabetes mellitus.

The US FDA has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes.

New 7.5 mg and 10 mg Zepbound single-dose vials now available for $499 per month via Zepbound Self Pay Journey Program 2.5 mg and 5 mg vial prices reduced INDIANAPOLIS ...

Women over 30 should include essential fruits like cherries, tomatoes, papaya, guava, apples, and avocados in their diet.

Treating older people with diabetes is challenging due to multiple medical comorbidities that might interfere with patients' ...

Sanofi (NASDAQ:SNY) has received FDA approval for Merilog, a biosimilar of Novo Nordisk's (NVO) rapid-acting insulin product NovoLog, for the improvement of glycemic control in adults and children ...

“Merilog, a rapid-acting human insulin ... in people with diabetes. The approval is for both a 3 milliliter single-patient-use prefilled pen and a 10 milliliter multiple-dose vial.

While Ozempic is approved by the FDA to treat type 2 diabetes, it’s not considered a treatment for type 1 diabetes. Ozempic enhances insulin production ... s used and that dosage should ...

Merilog, a rapid-acting human insulin ... people with diabetes. The approval is for both a 3 milliliter (mL) single-patient-use prefilled pen and a 10 milliliter (mL) multiple-dose vial.

Sliding scale insulin therapy involves following a chart of insulin dosages ... for people with noncritical type 2 diabetes who are in the hospital. The dose will change throughout the day.

Intermittent fasting can also positively affect the circadian rhythms of gut biology and the release of insulin and growth ... stopping or reducing the dose of some diabetes medications, diuretics ...

Glytec's industry-leading SaaS platform, trusted by 350+ hospitals, empowers collaborative diabetes management and insulin dosing—improving patient outcomes, reducing length of stay, and streamlining ...